We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+57.75%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.48B
AUM Growth
+$1.48B
Cap. Flow
+$437M
Cap. Flow %
9.75%
Top 10 Hldgs %
48.38%
Holding
120
New
23
Increased
28
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$58.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$55.9M
3
AXSM icon
Axsome Therapeutics
AXSM
+$37.2M
4
SYRE icon
Spyre Therapeutics
SYRE
+$34.8M
5
ABBV icon
AbbVie
ABBV
+$34.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$74M
2
IMVT icon
Immunovant
IMVT
+$54.7M
3
ROIV icon
Roivant Sciences
ROIV
+$44.6M
4
HRMY icon
Harmony Biosciences
HRMY
+$32.6M
5
RLAY icon
Relay Therapeutics
RLAY
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
51
Solid Biosciences
SLDB
$802M
$21.5M 0.48%
3,495,933
– –
ISRG icon
52
Intuitive Surgical
ISRG
$127B
$18.6M 0.41%
+55,000
New +$16.4M
AORT icon
53
Artivion
AORT
$1.34B
$16.7M 0.37%
931,352
– –
ASND icon
54
Ascendis Pharma A/S
ASND
$16.6B
$16.6M 0.37%
+132,176
New +$13.2M
TMCI icon
55
Treace Medical Concepts
TMCI
$257M
$15.9M 0.36%
1,250,405
-583,655
-32% -$5.9M
MIRM icon
56
Mirum Pharmaceuticals
MIRM
$6.69B
$15.8M 0.35%
534,942
-137,100
-20% -$4.15M
ACRV icon
57
Acrivon Therapeutics
ACRV
$60.8M
$14.8M 0.33%
3,007,858
– –
ARVN icon
58
Arvinas
ARVN
$530M
$14.6M 0.33%
+354,082
New +$8.28M
APLT
59
DELISTED
Applied Therapeutics
APLT
$13.7M 0.31%
+4,080,249
New +$10.2M
EYPT icon
60
EyePoint Inc
EYPT
$988M
$13.6M 0.3%
+589,646
New +$6.59M
LONA
61
LeonaBio Inc
LONA
$67M
$13.1M 0.29%
540,296
+60,568
+13% +$1.07M
AUTL
62
Autolus Therapeutics
AUTL
$381M
$11.8M 0.26%
+1,831,167
New +$6.98M
ZYME icon
63
Zymeworks
ZYME
$1.62B
$11.2M 0.25%
1,074,807
-371,316
-26% -$2.96M
TNGX icon
64
Tango Therapeutics
TNGX
$4.22B
$11M 0.25%
1,111,870
-1,307,098
-54% -$11.3M
TCMD icon
65
Tactile Systems Technology
TCMD
$618M
$10.1M 0.23%
707,159
– –
PTGX icon
66
Protagonist Therapeutics
PTGX
$8.61B
$8.79M 0.2%
383,260
-671,013
-64% -$11.7M
ITCI
67
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.73M 0.17%
+108,000
New +$6.21M
OLMA icon
68
Olema Pharmaceuticals
OLMA
$991M
$7.57M 0.17%
+539,831
New +$7.25M
TERN
69
DELISTED
Terns Pharmaceuticals
TERN
$6.98M 0.16%
1,075,000
– –
COGT icon
70
Cogent Biosciences
COGT
$6.76B
$6.6M 0.15%
1,122,958
-1,186,512
-51% -$9.09M
RGNX icon
71
Regenxbio
RGNX
$617M
$6.15M 0.14%
+342,408
New +$6.03M
EWTX icon
72
Edgewise Therapeutics
EWTX
$4.28B
$6.08M 0.14%
+555,555
New +$3.9M
MGNX icon
73
MacroGenics
MGNX
$237M
$5.89M 0.13%
+611,932
New +$4.23M
AXGN icon
74
Axogen
AXGN
$2.26B
$5.52M 0.12%
808,380
-67,518
-8% -$375K
LABP
75
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$5.44M 0.12%
1,486,991
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Perceptive Advisors held 120 positions worth $4.48B, up 49% from $3B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $437M of net new capital in Q4 2023, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was CARGO Therapeutics: 3,436,600 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunovant, an estimated $54.7M trimmed.

  • Perceptive Advisors's largest Q4 2023 buy was CARGO Therapeutics: 3,436,600 shares worth $79.6M.
  • Perceptive Advisors added most to Rhythm Pharmaceuticals in Q4 2023, an estimated $55.9M increase.
  • Perceptive Advisors's biggest Q4 2023 reduction was Immunovant, cutting an estimated $54.7M.
  • Perceptive Advisors fully exited argenx in Q4 2023, selling an estimated $74M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $4.48B portfolio in Q4 2023.
  • Perceptive Advisors opened 23 new positions and closed 19 in Q4 2023.
  • Perceptive Advisors's portfolio value rose 49% quarter-over-quarter to $4.48B.

Based on Perceptive Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.